ST. PAUL, Minn.,
Nov. 30, 2016 /PRNewswire/
-- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical
devices using neuroblocking technology to treat obesity, metabolic
diseases and other gastrointestinal disorders, today announced that
it will host a vBloc® Therapy commercialization and corporate
update conference call today at 11:00 AM
Eastern Time ahead of the Company's anticipated special
meeting of shareholders to be held Monday,
December 12, 2016. The call will be led by Dan W. Gladney, the Company's President, Chief
Executive Officer and Chairman of the Board.
Conference Call Details
The conference call may be accessed by dialing (877) 280-7473
(U.S. and Canada) or (707)
287-9370 (international), and entering passcode 25303017. A replay
of the call will be available from November
30, 2016 at 2:00 PM Eastern
Time through December 7, 2016
at 2:00 PM Eastern Time by dialing
(855) 859-2056 (U.S. and Canada)
or (404) 537-3406 (international) and entering passcode
25303017.
To access the live webcast, visit the events page of the
investor relations section of EnteroMedics' website at
www.enteromedics.com. A replay of the webcast will be available
immediately after the conference call.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of its neuroscience based
technology to treat obesity and metabolic diseases. vBloc®
Neurometabolic Therapy, delivered by a pacemaker-like device called
the vBloc® System, is designed to intermittently block the vagus
nerves using high-frequency, low-energy, electrical
impulses. EnteroMedics' vBloc® System has
received U.S. Food and Drug Administration approval and
CE Mark.
Information about the vBloc® System and vBloc®
Neurometabolic Therapy
You should not have an implanted vBloc® System if you have
cirrhosis of the liver, high blood pressure in the veins of the
liver, enlarged veins in your esophagus or a significant hiatal
hernia of the stomach; if you need magnetic resonance imaging
(MRI); if you have a permanently implanted, electrical medical
device; or if you need a diathermy procedure using heat. The most
common related adverse events that were experienced during clinical
study of the vBloc System included pain, heartburn, nausea,
difficulty swallowing, belching, wound redness or irritation, and
constipation.
Talk with your doctor about the full risks and benefits of vBloc
Therapy and vBloc System. For additional prescribing information,
please visit www.enteromedics.com.
If you are interested in learning more about vBloc
Neurometabolic Therapy, please
visit www.vbloc.com or call
1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements
about EnteroMedics Inc. Our actual results could differ
materially from those discussed due to known and unknown risks,
uncertainties and other factors including our limited history of
operations; our losses since inception and for the foreseeable
future; our limited commercial sales experience with our vBloc®
System for the treatment of obesity in the United
States or in any foreign market other
than Australia and the European Community; our ability to
regain and then maintain compliance with the Nasdaq continued
listing requirements; our ability to commercialize our vBloc®
System; our dependence on third parties to initiate and perform our
clinical trials; the need to obtain regulatory approval for any
modifications to our vBloc® System; physician adoption of our
vBloc® System and vBloc® Neurometabolic Therapy; our ability to
obtain third party coding, coverage or payment levels; ongoing
regulatory compliance; our dependence on third party manufacturers
and suppliers; the successful development of our sales and
marketing capabilities; our ability to raise additional capital
when needed; international commercialization and operation; our
ability to attract and retain management and other personnel and to
manage our growth effectively; potential product liability claims;
potential healthcare fraud and abuse claims; healthcare legislative
reform; and our ability to obtain and maintain intellectual
property protection for our technology and products. These and
additional risks and uncertainties are described more fully in the
Company's filings with the Securities and Exchange Commission,
particularly those factors identified as "risk factors" in the
annual report on Form 10-K filed March 28, 2016. We are
providing this information as of the date of this press release and
do not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
Logo - http://photos.prnewswire.com/prnh/20160502/362531LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/enteromedics-to-host-vbloc-therapy-commercialization-and-corporate-update-conference-call-300370127.html
SOURCE EnteroMedics Inc.